Home›Trastuzumab›Trastuzumab + Trastuzumab Qyyp

Does Trastuzumab Interact with Trastuzumab Qyyp?

CDI records a major classification for Trastuzumab and Trastuzumab Qyyp. The stored summary is: 7 DRUG INTERACTIONS Anthracyclines Patients who receive anthracycline after stopping trastuzumab products may be at increased risk of cardiac dysfunction because of trastuzumab products estimated long washout period [see Clinical Pharmacology (12.3) ] . If possible, avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab products. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Evidence status

A current label comparison is not yet available for this record. The summary and severity are stored CDI information; they have not been independently validated on this page against the exact product label.

Confirm the medicine, formulation, route, and applicable warning with your pharmacist or prescriber. Independent clinical review has not been recorded.

Stored CDI classification
Major
Trastuzumab Class
HER2/neu Receptor Antagonist
Trastuzumab Qyyp Class
HER2/neu Receptor Antagonist
Management
Confirm exact products with your pharmacist
Data Source
U.S. FDA via OpenFDA

What To Tell Your Doctor or Pharmacist

If you are taking Trastuzumab and your doctor is considering prescribing Trastuzumab Qyyp (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Trastuzumab(Herceptin)+💊 Trastuzumab Qyyp(Trazimera)

Severity & Interaction Details

⚠️
major
Stored CDI classification: major
A current source comparison has not been recorded for this claim. The stored classification does not determine the clinical significance for your exact products or circumstances.
Severity scale
MinorContra
On record
Yes
Drug A class
HER2/neu Receptor Antagonist
Drug B class
HER2/neu Receptor Antagonist
Source
FDA drug label - trastuzumab-qyyp

What this means in plain English

7 DRUG INTERACTIONS Anthracyclines Patients who receive anthracycline after stopping trastuzumab products may be at increased risk of cardiac dysfunction because of trastuzumab products estimated long washout period [see Clinical Pharmacology (12.3) ] . If possible, avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab products.

About Trastuzumab and Trastuzumab Qyyp

Trastuzumab and Trastuzumab Qyyp both belong to the HER2/neu Receptor Antagonist class. You may recognize them by the brand names Herceptin and Trazimera. Both Trastuzumab and Trastuzumab Qyyp carry an FDA boxed warning — the agency's most serious safety designation.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: FDA drug label - trastuzumab-qyyp

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Trastuzumab and Trastuzumab Qyyp against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.

CDI: source-linked explanations